Medium Biosciences Analysis: $125K Raised
What is Medium Biosciences?
Medium Biosciences turns advances in AI and protein design into experimentally validated molecular tools for research and diagnostics. The company builds custom affinity reagents for targets that customers need to bind, detect, capture, or measure. It reports 25 plus completed projects, 20 plus engineered proteins, and 10 plus customers across industry and academia.
Location
San Francisco, United States
Employees
1-10
Founded
2021
Product Features & Capabilities
- AI-designed protein therapeutics, development of AI models, creation of functional therapeutic proteins, innovative assays for biomolecule design, focus on antibodies.
How much Medium Biosciences raised
1 - $125K
September 1, 2021Lead Investor: Y Combinator
Who are the founders of Medium Biosciences
MH
Mohamed Hassan Kane
Co-Founder & CEO
FA
Frances Anastassacos
Co-Founder
Competitors Overview
Medium Biosciences operates in the field of AI-designed protein therapeutics, where it faces competition from several notable companies:
-
Generate Biomedicines: This company is at the intersection of machine learning, biological engineering, and medicine. They focus on pioneering generative biology to create breakthrough medicines. Their approach allows for the design of novel proteins with specific therapeutic functions, which can be a significant advantage in developing targeted treatments.
-
Archon Biosciences: Archon is developing geometrically tunable protein therapeutics, leveraging structural innovation to create new therapeutic opportunities. Their focus on the structural aspects of protein design may provide them with unique advantages in creating more effective biologics.
Both competitors utilize advanced technologies in protein design, but their specific focuses—generative biology for Generate Biomedicines and structural innovation for Archon Biosciences—distinguish them from Medium Biosciences.
Market Focus
Medium Biosciences primarily focuses on the biotechnology industry, specializing in AI-designed protein therapeutics.
Investors
- Y Combinator
- AIX Ventures
- E14 Fund
- Emily Leproust
- Village Global
- SBXi
See something that needs updating? Suggest edits to this profile.